{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:46:24Z","timestamp":1792683984166,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000152","name":"Canadian Hemophilia Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106912","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:48:28Z","timestamp":1786981708000},"page":"106912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-8167","authenticated-orcid":false,"given":"Jerome","family":"Teitel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Thillaye-Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidushi","family":"Swarup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bouskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106912_bib1","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106912_bib3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106912_bib4","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.106912_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/17474086.2024.2402304","article-title":"Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies","volume":"17","author":"Mahlangu","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"Suppl 4","key":"10.1016\/j.rpth.2026.106912_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102915","article-title":"Real-world data: bridging the gap between clinical trials and practice","volume":"78","author":"Wilson","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.rpth.2026.106912_bib12","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106912_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/hae.15015","article-title":"Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry","volume":"30","author":"van der Zwet","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102415","article-title":"Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review","volume":"8","author":"Young","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib15","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.rpth.2026.106912_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2516.2012.02813.x","article-title":"Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States","volume":"18","author":"Duncan","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000121828","article-title":"Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective","volume":"119","author":"Khair","year":"2008","journal-title":"Acta Haematol"},{"key":"10.1016\/j.rpth.2026.106912_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","article-title":"Barriers to compliance with prophylaxis therapy in haemophilia","volume":"7","author":"Hacker","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2025-537","article-title":"Mim8 prophylaxis in adults and adolescents with hemophilia A: 52-week efficacy and safety outcomes from the phase 3 FRONTIER2 study","volume":"146","author":"Lentz","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106912_bib20","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood.2025031894","article-title":"NXTAGE: a phase 1\/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors","volume":"147","author":"Nogami","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106912_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/rth2.12106","article-title":"Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations","volume":"2","author":"Iorio","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17474086.2025.2574715","article-title":"Quantifying the optimal factor VIII levels to achieve patient-centric and clinician-relevant outcomes among people with hemophilia A: a SHELF elicitation study","volume":"19","author":"Burke","year":"2026","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106912_bib23","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106912_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","article-title":"Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review","volume":"60","author":"Donners","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106912_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/hae.14785","article-title":"Low dose emicizumab prophylaxis in haemophilia A patients: a pilot study from India","volume":"29","author":"Bansal","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jtha.2023.12.023","article-title":"Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients","volume":"22","author":"Patil","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib28","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/hae.15062","article-title":"Reduced doses of emicizumab achieve good efficacy: results from a national-wide multicentre real-world study in China","volume":"30","author":"Xu","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.106912_bib30","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/hae.70085","article-title":"Estimating the factor VIII-equivalent activity of emicizumab using global assays of haemostasis","volume":"31","author":"Kraemmer","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib31","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s40262-020-00904-z","article-title":"Population pharmacokinetic analysis and exploratory exposure-bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A","volume":"59","author":"Retout","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.rpth.2026.106912_bib32","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2021-150627","article-title":"Which level of emicizumab is necessary for a good hemostasis?","volume":"138","author":"Ciavarella","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106912_bib33","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40262-021-01042-w","article-title":"Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review","volume":"60","author":"Donners","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106912_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102705","article-title":"Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study","volume":"9","author":"Angchaisuksiri","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003088-199325020-00003","article-title":"Clinical pharmacokinetics of drugs in obesity. An update","volume":"25","author":"Cheymol","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2026.106912_bib37","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/hae.14644","article-title":"Emicizumab dose capping in obese patients with Haemophilia A: early outcomes at a single centre","volume":"28","author":"Krumb","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib38","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jtha.2024.02.009","article-title":"Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data","volume":"22","author":"Cho","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib39","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/hae.14398","article-title":"Low immunogenicity of emicizumab in persons with haemophilia A","volume":"27","author":"Schmitt","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib40","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/a-1127-6476","article-title":"Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A","volume":"40","author":"Holstein","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.106912_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/hae.14172","article-title":"Management of patients with severe haemophilia A without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET","volume":"26","author":"Coppola","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib43","article-title":"Pharmacodynamic interaction between emicizumab and coagulation factor VIII","author":"Chill","year":"2026","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106912_bib44","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106912_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2023.01.007","article-title":"In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab","volume":"222","author":"Yamaguchi","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106912_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17474086.2021.1875817","article-title":"Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors","volume":"14","author":"Carcao","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106912_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/hae.70253","article-title":"Nonfactor replacement treatment and surgery in haemophilia: evidence from the literature and selected clinical cases","author":"Carulli","year":"2026","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/hae.70271","article-title":"Treatment of haemophilia A without inhibitors: real-world treatment patterns and clinical outcomes in the US","volume":"32","author":"Wheeler","year":"2026","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/20406207261419325","article-title":"Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A","volume":"17","author":"Dutta","year":"2026","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106912_bib50","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/jcm12062317","article-title":"Safe and successful surgical outcome in persons with hemophilia A with and without inhibitors treated with emicizumab: a large, single center, real-world experience","volume":"12","author":"Castaman","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.106912_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106912_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12959-026-00868-3","article-title":"Transition to emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study","volume":"24","author":"Ye","year":"2026","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2026.106912_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70623","article-title":"Long-term outcomes with emicizumab prophylaxis for haemophilia A in China: a multicentre, large-cohort retrospective study","author":"Xu","year":"2026","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106912_bib54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17474086.2022.2112171","article-title":"Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A","volume":"15","author":"Sun","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106912_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/cer-2021-0278","article-title":"Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A","volume":"11","author":"Mahajerin","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.rpth.2026.106912_bib56","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17474086.2023.2198207","article-title":"A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors","volume":"16","author":"Escobar","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106912_bib57","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1080\/03007995.2022.2105072","article-title":"A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab","volume":"38","author":"Batt","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rpth.2026.106912_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103164","article-title":"Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors\u2019 Organisation","volume":"9","author":"Wall","year":"2025","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:25:36Z","timestamp":1792682736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035703"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106912","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106912"}}